Free Trial

Palisade Bio (PALI) Competitors

Palisade Bio logo
$1.85 0.00 (0.00%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$1.87 +0.02 (+1.08%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PALI vs. HYPD, ALGS, ICCC, DRRX, ACRV, GNTA, SKYE, TELO, CUE, and TLPH

Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Hyperion DeFi (HYPD), Aligos Therapeutics (ALGS), ImmuCell (ICCC), DURECT (DRRX), Acrivon Therapeutics (ACRV), Genenta Science (GNTA), Skye Bioscience (SKYE), Telomir Pharmaceuticals (TELO), Cue Biopharma (CUE), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.

Palisade Bio vs. Its Competitors

Palisade Bio (NASDAQ:PALI) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Palisade Bio has higher revenue and earnings than Hyperion DeFi. Palisade Bio is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Palisade Bio$250K67.49-$14.44M-$4.06-0.46
Hyperion DeFi$60K938.44-$49.82M-$58.40-0.14

Palisade Bio has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 0.7% of Palisade Bio shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Palisade Bio presently has a consensus price target of $12.00, suggesting a potential upside of 548.65%. Hyperion DeFi has a consensus price target of $2.00, suggesting a potential downside of 75.28%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Palisade Bio is more favorable than Hyperion DeFi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Hyperion DeFi
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, Palisade Bio had 4 more articles in the media than Hyperion DeFi. MarketBeat recorded 7 mentions for Palisade Bio and 3 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.83 beat Palisade Bio's score of 0.45 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Palisade Bio
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hyperion DeFi
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Palisade Bio has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Palisade Bio's return on equity of -214.94% beat Hyperion DeFi's return on equity.

Company Net Margins Return on Equity Return on Assets
Palisade BioN/A -214.94% -135.09%
Hyperion DeFi -62,238.41%-876.25%-181.67%

Summary

Palisade Bio beats Hyperion DeFi on 10 of the 16 factors compared between the two stocks.

Get Palisade Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PALI vs. The Competition

MetricPalisade BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$16.87M$3.35B$6.04B$10.51B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-0.4621.9085.1027.24
Price / Sales67.49422.17556.60219.52
Price / CashN/A46.9537.5761.53
Price / Book0.6810.4312.346.74
Net Income-$14.44M-$52.58M$3.32B$276.59M
7 Day Performance-7.50%-1.55%-1.33%-0.47%
1 Month Performance212.50%12.96%8.12%7.47%
1 Year Performance-47.89%15.43%73.80%34.58%

Palisade Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PALI
Palisade Bio
2.1035 of 5 stars
$1.85
flat
$12.00
+548.6%
-45.7%$16.87M$250K-0.4610
HYPD
Hyperion DeFi
0.5807 of 5 stars
$8.77
-15.6%
$2.00
-77.2%
-77.9%$61.03M$44.44K-0.1540Gap Down
ALGS
Aligos Therapeutics
3.8849 of 5 stars
$9.80
-4.1%
$50.00
+410.2%
+33.6%$60.28M$3.17M-0.5090News Coverage
ICCC
ImmuCell
1.1268 of 5 stars
$6.58
+3.6%
N/A+82.6%$59.55M$26.49M34.6370Gap Up
DRRX
DURECT
1.125 of 5 stars
$1.91
flat
N/AN/A$59.31M$1.66M-19.1080
ACRV
Acrivon Therapeutics
2.4636 of 5 stars
$1.91
-0.3%
$15.00
+687.4%
-76.0%$59.18MN/A-0.8458
GNTA
Genenta Science
0.9158 of 5 stars
$3.18
-1.2%
N/A-46.3%$58.16MN/A0.007
SKYE
Skye Bioscience
2.7421 of 5 stars
$1.86
-2.4%
$9.80
+428.3%
-62.8%$57.18MN/A-1.7411High Trading Volume
TELO
Telomir Pharmaceuticals
2.7933 of 5 stars
$1.76
+23.6%
$15.00
+754.7%
-65.2%$56.94MN/A-3.271News Coverage
Gap Up
High Trading Volume
CUE
Cue Biopharma
2.4855 of 5 stars
$0.74
+1.0%
N/A-34.1%$56.48M$8.29M-1.3160Analyst Forecast
TLPH
Talphera
1.7674 of 5 stars
$1.25
+13.3%
$5.00
+301.3%
+46.7%$55.62M$650K-3.0519Gap Up

Related Companies and Tools


This page (NASDAQ:PALI) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners